LLY compared with SPRB: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

SPRBSpruce Biosciences, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

SPRBSpruce Biosciences, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

SPRB1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+1.42%—

= impliedLLY realized, solidSPRB realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedSource: market data

LLYELI Lilly & Co

1,371.32▼−3.29%· post 1,363.77

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

SPRBSpruce Biosciences, Inc.

43.35▼−6.99%· post 41.23

ClosedNov 5 '26

Mkt cap$134.0MRevenue$697,000Q4 FY24Revenue$5MFY24

Compare

ClosedNov 5 '26

LLYELI Lilly & Co

SPRBSpruce Biosciences, Inc.

1,371.32▼−3.29%post 1,363.77

Price

43.35▼−6.99%post 41.23

$1.2T

Mkt cap

$134.0M

Q3 FY26$24.4B

Revenue

$697,000Q4 FY24

FY25$65.2B

Revenue

$5MFY24

LLY1,371.32▼−3.29%vsSPRB43.35▼−6.99%ClosedNov 5 '26